Here are two brief analogies to describe Cingulate:

• Cingulate is like an early-stage Supernus Pharmaceuticals, focused on developing new formulations for well-known ADHD and anxiety treatments.

• Think of Cingulate as a specialized biotech aiming to create next-generation versions of popular ADHD drugs, similar to how Jazz Pharmaceuticals innovates with new formulations for neurological conditions.

```html

• CTx-1301 (dexmethylphenidate): A product candidate for the treatment of attention deficit/hyperactivity disorders.
• CTx-1302 (dextroamphetamine): A product candidate for the treatment of attention deficit/hyperactivity disorders.
• CTx-2103: A product candidate under development for the treatment of anxiety disorders.

```

As a clinical-stage biopharmaceutical company, Cingulate Inc. (CING) is primarily focused on the research, development, and clinical trials of its product candidates for central nervous system and neurobiological disorders. The company has not yet commercialized any products, nor does it generate revenue from product sales.

Therefore, Cingulate Inc. does not currently have major commercial customers, either companies or categories of individuals, that it sells products or services to in the traditional sense.

ANI Pharmaceuticals, Inc. (Symbol: ANIP)

LGM Pharma LLC

Shane J. Schaffer, PharmD - Chief Executive Officer and Chairman Dr. Schaffer is a Co-Founder of Cingulate Therapeutics and has served as CEO since its inception in 2012. He is a 25-year pharmaceutical industry veteran with extensive experience in pharmaceutical drug development, commercialization, and biotech commercial operations. Throughout his career, he has held positions at Pfizer, Novartis, and Sanofi (including predecessor companies). Dr. Schaffer's leadership has been instrumental in various business aspects, including product launches, brand planning, joint venture brand management, life cycle management, and market development. He co-founded Cingulate Therapeutics LLC in January 2013, driven by his passion for developing drug-delivery technology for ADHD and anxiety disorders. From August 2025 to December 2025, he was on administrative leave due to a personal legal matter and was reinstated as CEO on December 15, 2025. Jennifer Callahan, CPA - Chief Financial Officer Jennifer Callahan was named Cingulate's Chief Financial Officer in January 2024. She brings decades of finance and accounting experience to the company, having served as Vice President, Corporate Controller for Cingulate from 2017 until her promotion to CFO. Prior to joining Cingulate, Ms. Callahan served as the Director of Accounting for a local Kansas City area CPA firm and has provided consulting services to both publicly and privately owned companies across various industries. She began her career with Deloitte in their audit practice. In August 2025, she was appointed interim CEO when Dr. Schaffer was on administrative leave, and she resumed her sole duties as Chief Financial Officer in December 2025. Nilay Patel, JD - Chief Legal Officer Nilay Patel serves as Chief Legal Officer of Cingulate Inc., bringing over 20 years of legal, compliance, and operational leadership experience across the pharmaceutical and biotechnology industries. He possesses deep expertise in legal strategy, healthcare compliance, intellectual property, and corporate governance. Before joining Cingulate, Mr. Patel held the roles of Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary at Ironshore Pharmaceuticals, where he played a significant role in launching the company's flagship ADHD therapy. Matthew Brams, MD - Chief Medical Officer and Co-Founder Dr. Matthew Brams is Chief Medical Officer and a Co-Founder of Cingulate Therapeutics. He is the Medical Director and Principal of Bayou City Research, Inc., and has been instrumental in securing FDA approval for over 15 Central Nervous System drugs currently available in the market. Dr. Brams has served as a lead investigator in numerous pivotal trials for drugs targeting ADHD, autism, bipolar disorder, and schizophrenia therapeutic areas. His experience includes over 125 clinical trials in both adult and pediatric populations across various psychiatric fields. He also has more than 25 years of clinical experience in managing patients with Adult and Child Psychiatry, with particular expertise in ADHD and Autistic Spectrum Disorders. Bryan Downey - Chief Commercial Officer Bryan Downey was appointed Chief Commercial Officer in November 2025. He brings over 25 years of experience in commercial strategy, leadership, and business transformation, with a proven track record of successful pharmaceutical product launches. Mr. Downey has held senior executive roles at Alfasigma USA and Jubilant Pharma, where he led commercial operations and product commercialization efforts. Most recently, he served as Managing Director in CRA | Admired Leadership's Leadership Advisory Practice, advising Fortune 100 and biopharma executives on leadership, strategy, and organizational excellence.

The key risks to Cingulate Inc. (CING) primarily revolve around its status as a clinical-stage biopharmaceutical company with lead product candidates for central nervous system and neurobiological disorders. These risks include:

1. Regulatory Approval and Clinical Trial Success: Cingulate's future hinges on the successful regulatory approval and subsequent commercial launch of its lead asset, CTx-1301, for Attention-Deficit/Hyperactivity Disorder (ADHD). While the FDA accepted its New Drug Application (NDA) for CTx-1301 with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026, there remains a critical risk that the FDA could still reject the NDA. Such a rejection would invalidate years of research and development and significantly jeopardize the company's viability.
2. Financial Health and Need for Additional Capital: As a clinical-stage company, Cingulate has a history of operating losses and anticipates incurring substantial costs for the foreseeable future, without current profitability. The company's cash and cash equivalents were approximately $6.1 million as of September 30, 2025, which is expected to cover capital needs only into the second quarter of 2026. To support commercialization efforts through the anticipated PDUFA date for CTx-1301, Cingulate will need to raise an estimated $7.0 million in additional capital. The inability to secure sufficient additional funding when needed poses a significant risk to its operations and ability to commercialize its products.
3. Competition and Market Adoption: Even if CTx-1301 receives FDA approval, Cingulate operates in a highly competitive ADHD market. The company aims to differentiate its product with a "once-daily" formulation designed to improve adherence and provide full-day efficacy. However, there is a risk that CTx-1301 may not achieve substantial market share against existing extended-release stimulants, or that competitors could introduce similar or superior formulations.

null

Cingulate's main product candidates target the Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety disorder markets.

For their ADHD product candidates, CTx-1301 and CTx-1302 (dexmethylphenidate and dextroamphetamine), the addressable market sizes are:

• U.S. Market: Cingulate states that CTx-1301 and CTx-1302 are being developed to serve an approximate $18 billion annual U.S. ADHD market. Another company statement indicates an approximate $22.1 billion annual U.S. ADHD market. Recent market reports provide varying estimates, with the U.S. ADHD therapeutics market size valued at USD 5.47 billion in 2025, projected to reach USD 6.68 billion by 2035. Other estimates for the U.S. market include USD 9,892.1 million in 2023, expected to reach USD 12,562.5 million by 2030, and reaching USD 10.2 billion by the end of 2032. Some estimates place the total U.S. ADHD market at over US$20 billion.

• Global Market: The global ADHD therapeutics market size is valued at USD 14.96 billion in 2025 and is expected to reach USD 23.89 billion by 2035. Other projections indicate the global ADHD therapeutics market was valued at USD 35.17 billion in 2024, projected to reach USD 38.37 billion in 2025 and USD 76.96 billion by 2033. Another report estimates the global Attention-Deficit Hyperactivity Disorder (ADHD) Market at USD 18.75 billion in 2024, expected to reach USD 32.90 billion by 2032.

For their anxiety disorder product candidate, CTx-2103, the addressable market sizes are:

• U.S. Market: Cingulate is developing CTx-2103 to serve the roughly $5 billion U.S. anxiety market. More specifically, CTx-2103 targets the $5.5 billion U.S. anxiety market. In 2020, sales for the active pharmaceutical ingredient in CTx-2103 accounted for over $2 billion of sales within the $5.2 billion anxiety market in the United States. The U.S. Generalized Anxiety Disorder Treatment Market generated nearly USD 1,019 million in 2023 and is expected to experience significant growth. The USA is projected to account for USD 17.9 billion of the global Anxiety Disorders and Depression Treatment Market by 2035.

• Global Market: The global anxiety market is estimated at $11.6 billion. Projections indicate the global anxiety disorders treatment market will increase from USD 12.33 billion in 2025 to USD 17.56 billion by 2035. The global anxiety disorders treatment market size is calculated at USD 11.59 billion in 2024 and is expected to reach around USD 15.90 billion by 2032. Another source estimates the global anxiety disorders and depression treatment market size at USD 15.42 billion in 2024, projected to reach USD 19.28 billion by 2030. The global anxiety disorders and depression treatment market is expected to grow from USD 22.65 billion in 2025 to USD 30.49 billion by 2031.

Expected Drivers of Future Revenue Growth for Cingulate (CING)

Over the next 2-3 years, Cingulate's revenue growth is anticipated to be driven by several key factors as the clinical-stage biopharmaceutical company advances its product pipeline utilizing its proprietary Precision Timed Release (PTR™) drug delivery platform:

1. Commercialization of CTx-1301 for ADHD: The most immediate and significant driver of future revenue growth is the potential commercial launch of CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Cingulate completed its Pre-NDA meeting with the FDA in April 2025 and submitted the New Drug Application (NDA) in mid-2025. The FDA accepted the NDA in October 2025 and set a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. Subject to FDA approval, a potential market launch for CTx-1301 is anticipated in 2026, targeting the substantial U.S. ADHD market.
2. Advancement of CTx-1302 for ADHD: Cingulate's second ADHD product candidate, CTx-1302 (dextroamphetamine), also leverages the PTR™ platform. This product is expected to advance towards an Investigational New Drug (IND) filing and the commencement of Phase 1/2 clinical studies in 2026. Progress in this pipeline candidate signals future market expansion within the ADHD therapeutic area and potential revenue generation beyond the initial 2-3 year timeframe, building on the success of CTx-1301.
3. Development and Potential Commercialization of CTx-2103 for Anxiety Disorders: The development of CTx-2103 for anxiety disorders represents an expansion into a new therapeutic area for Cingulate. The company received a $3 million grant in April 2025 to accelerate the development of this once-daily buspirone formulation, with the grant projected to cover development costs through mid-2026, aligning with the targeted timing for its IND submission. CTx-2103 aims to penetrate the global anxiety market, which was valued at $11.6 billion and is projected to reach approximately $15.90 billion by 2032.
4. Strategic Utilization and Validation of the Precision Timed Release (PTR™) Platform: The successful progression and anticipated commercialization of CTx-1301, along with the advancement of CTx-1302 and CTx-2103, will further validate Cingulate's proprietary PTR™ drug delivery platform. This validation could lead to the application of the platform to develop additional product candidates for other central nervous system and neurobiological disorders, potentially through internal development or strategic partnerships, thereby expanding the company's long-term revenue opportunities.

Share Issuance

• In September 2023, Cingulate completed a $4 million public offering of common stock and warrants and converted $5.8 million of debt into equity. This offering included the issuance of 1,720,000 shares of common stock, along with pre-funded warrants and Series A and B warrants for additional shares.
• The company raised $10.7 million in capital during early 2024, comprising $3.2 million from an At-the-Market (ATM) Offering and $7.5 million from a public offering of common stock and warrants in February 2024. An additional $3.3 million of debt was converted to equity in the same period.
• In February 2026, Cingulate closed a $12 million private investment in public equity (PIPE) financing, with potential total proceeds of up to $21.4 million. This financing involved common stock issued at $5.04 per share with 80% warrant coverage, and preferred shares convertible upon stockholder approval.

Inbound Investments

• Werth Family Investment Associates, LLC, managed by a Cingulate board member, converted $5.8 million of debt and accrued interest into pre-funded warrants for Cingulate common stock in September 2023.
• Falcon Creek Capital Advisor LLC led a $12 million private investment in public equity (PIPE) financing in February 2026, which included participation from life science-focused institutional investors. The total potential proceeds from this financing could reach up to $21.4 million.
• Cingulate has reportedly raised a total of $33 million in funding across six rounds, with The Werth Family Foundation identified as a significant investor.

Capital Expenditures

• In the 12 months leading up to November 2023, Cingulate reported capital expenditures of approximately -$204,387.
• For the third quarter of 2025, capital expenditures were reported as $0, representing a 100% decrease from the previous quarter.
• Research and development expenses, a primary focus of capital allocation, increased from $9.0 million in 2022 to $15.5 million in 2023, primarily due to heightened clinical activity for CTx-1301 Phase 3 studies.